About us Contacts Drug interactions: 390 212
Drug search by name

Spironolactone Oral Suspension and Zytiga

Determining the interaction of Spironolactone Oral Suspension and Zytiga and the possibility of their joint administration.

Check result:
Spironolactone Oral Suspension <> Zytiga
Relevance: 17.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using abiraterone together with spironolactone may reduce the effectiveness of abiraterone in treating prostate cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Concomitant use of abiraterone and spironolactone may increase prostate specific antigen (PSA) levels. The exact mechanism is unknown. It has been speculated that spironolactone may act as a mixed androgen receptor agonist/antagonist, and as such display both pro-androgenic and anti-androgenic effects. In two randomized placebo-controlled multicenter phase 3 trials evaluating the use of abiraterone with low dose prednisolone or prednisone in patients with metastatic castration-resistant prostate cancer, spironolactone use was not allowed due to its potential to bind to the androgen receptor and increase PSA levels. In addition, in a case report of an 80 year-old man with heavily pretreated metastatic castration-resistant prostate cancer on abiraterone therapy, introduction of spironolactone for concomitant heart failure led to development of significant bone pain and biochemical progression (increased PSA and alkaline phosphatase levels) of his prostate cancer within a week of starting spironolactone. However, the symptoms of bone pain and increased PSA and alkaline phosphatase levels resolved within 2 weeks of spironolactone treatment withdrawal.

MANAGEMENT: Caution is recommended if abiraterone is to be used in combination with spironolactone in patients with metastatic castration-resistant prostate cancer. If this combination is used, monitoring for worsening clinical symptoms and increased levels biochemical markers of prostate cancer such as PSA and alkaline phosphatase levels should be considered.

References
  • Ferraldeschi R, Sharifi N, Auchus RJ, Attard G "Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer." Clin Cancer Res 19 (2013): 3353-9
  • Sundar S, Dickinson PD "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate." BMJ Case Rep 2012 (2012): 1-4
  • "Product Information. Zytiga (abiraterone)." Centocor Inc, Malvern, PA.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Spironolactone Oral Suspension

Generic Name: spironolactone

Brand name: Aldactone, CaroSpir

Synonyms: Spironolactone

Zytiga

Generic Name: abiraterone

Brand name: Yonsa, Zytiga

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle